Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
March 19 2009 - 1:06PM
Marketwired
Marshall Edwards, Inc. (NASDAQ: MSHL) is pleased to announce the
appointment of Leah Cann to the Board of Directors of the Company.
Ms. Cann is an independent research analyst in Newport, Rhode
Island. She began her career as a research scientist with Memtec
Corporation and moved to Wall Street in 1992, where she was a
research analyst with CIBC Oppenheimer for nearly nine years. Ms.
Cann was a heath care analyst for the Boston-based asset manager,
Cadence Capital, and later the senior biotechnology analyst for
Wachovia Securities. Twice recognized as an All-Star analyst by the
Wall Street Journal, she is the founder of Leah Rush Cann Research
and Consulting, LLC, a Newport, Rhode Island-based cancer research
and consulting organization. She is also Founder and Chairman of
the Board of Hope Funds for Cancer Research, and a member of the
New York Academy of Sciences.
Ms. Cann received a BA in Art History and Chemistry and an MBA
from Stetson University. She was a post-baccalaureate at the
College of William and Mary and a post-graduate at Columbia
University. She has been a trustee and member of several committees
of International House in New York City for more than 10 years.
Marshall Edwards' Board Chairman, Professor Bryan Williams,
welcomed Ms. Cann to the Board. She has been appointed chair of the
Company Audit Committee.
The Company also announces that Mr. William D. Rueckert has
resigned from the Marshall Edwards' Board, and has accepted a
position on the Board of the Company's 72 per cent shareholder,
Novogen Limited. Chairman Williams, on behalf of the board and
shareholders, thanked Mr. Rueckert for his skillful and effective
contributions as a Marshall Edwards' director.
About Marshall Edwards, Inc. and Novogen Limited
Marshall Edwards is a specialist oncology company focused on the
clinical development of novel anti-cancer therapeutics. These
derive from a flavonoid technology platform that has generated a
number of novel compounds characterized by broad ranging activity
in laboratory testing against a range of cancer targets with few
side effects. The ability of these compounds to inhibit the
production of pro-survival proteins within the cancer cell suggests
that they may possess a unique combination of efficacy and safety.
Marshall Edwards has licensed rights from Novogen Limited (ASX:
NRT) (NASDAQ: NVGN) to bring oncology drugs including phenoxodiol
and triphendiol (NV-196) to market globally. Marshall Edwards is
majority owned by Novogen, an Australian biotechnology company that
is specializing in the development of therapeutics based on a
flavonoid technology platform. Novogen, based in Sydney, Australia,
is developing a range of therapeutics from its proprietary
flavonoid synthetic chemistry technology platform. More information
on phenoxodiol, triphendiol and on the Novogen group of companies
can be found at www.marshalledwardsinc.com and www.novogen.com.
More information about Marshall Edwards' Phase III clinical
trial Ovature, in which phenoxodiol is being studied in conjunction
with weekly carboplatin for its efficacy in treating advanced
ovarian cancer can be found by visiting www.ovaturetrial.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Christopher Naughton + 61 2 9878 0088 (Australia) Email
Contact
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024